Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase II study in patients with advanced and/refractory cervical cancer,
endometrial carcinoma or uterine sarcoma.
Patients will be treated with an immunomodulatory cocktail (Vitamin D, aspirin,
Cyclophosphamide and Lansoprazole), followed by pembrolizumab, combined with radiation. In
addition, patients will take Curcumin, a food supplement.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Ghent
Collaborators:
Anticancer Fund, Belgium Kom Op Tegen Kanker
Treatments:
Aspirin Curcumin Cyclophosphamide Dexlansoprazole Lansoprazole Pembrolizumab Vitamin D Vitamins